Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $6.8750.

A number of brokerages have issued reports on SRTS. Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Thursday, January 22nd. Alliance Global Partners assumed coverage on Sensus Healthcare in a research note on Friday, March 6th. They set a “buy” rating and a $7.50 price objective on the stock. Finally, Maxim Group dropped their price objective on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th.

Sensus Healthcare Stock Down 2.1%

SRTS opened at $4.11 on Friday. The firm has a 50-day moving average price of $4.33 and a 200-day moving average price of $3.99. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $5.92. The company has a market capitalization of $67.65 million, a price-to-earnings ratio of -8.74 and a beta of 1.28.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The business had revenue of $4.94 million for the quarter, compared to analysts’ expectations of $8.35 million. Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%. On average, sell-side analysts expect that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of SRTS. Opes Wealth Management LLC bought a new position in shares of Sensus Healthcare in the third quarter valued at approximately $50,000. XTX Topco Ltd bought a new stake in Sensus Healthcare during the 4th quarter worth approximately $77,000. Jane Street Group LLC bought a new stake in Sensus Healthcare during the 4th quarter worth approximately $79,000. Mindset Wealth Management LLC lifted its stake in Sensus Healthcare by 28.1% in the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Ingalls & Snyder LLC purchased a new stake in Sensus Healthcare in the 4th quarter worth approximately $219,000. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.